fig1

The role of immune checkpoint inhibitors and/or Yttrium-90 radioembolization in the management of hepatocellular carcinoma: challenges of treatment sequence

Figure 1. Mechanism of immune checkpoints in HCC in the absence (A) and presence (B) of ICI. This figure was re-printed with copyright permission from Mohr et al.[12]. HCC: Hepatocellular carcinoma; ICI: Immune checkpoint inhibitors; APC: antigen-presenting cell; MHC: major histocompatibility complex; TCR: T cell receptor; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; PD-1: programmed cell death 1 protein; PD-L1: programmed death-ligand 1.

Hepatoma Research
ISSN 2454-2520 (Online) 2394-5079 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/